Many thanks to VIB for joining BioFIT 2018 as a Bronze Sponsor!

 VIB is a life sciences research institute, based in Flanders, Belgium. They perform basic research with a strong focus on translatin​g scientific results into pharmaceutical, agricultural and industrial applications.

Join key BioFIT 2018 sponsors such as Bayer, RocheMSDBoehringer Ingelheim, Pfizer and LFB, to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

 

They were the BioFIT 2017 sponsors: Sanofi, Pfizer, Bayer, Genfit, Lilly, MSD, Merck, Boehringer Ingelheim, Johnson & Johnson Innovation, Novo Nordisk, LFB, PPRS and Trianni.

For more information about the sponsorship opportunities, visit the dedicated site page.

The BioFIT Steering Committee is glad to announce the BioFIT 2018 preliminary conference programme:

PLENARY SESSION: Seed funds crossing borders: How far and how fast is the early-stage investment market in Biotech globalising?

Globalisation of seed investment can be seen as traditionally geographically anchored, now early-stage investors tend to invest in more diversified areas. Where does the money come from? How far is this evolution towards more global funds going? How fast is it going in the investment community? Will it make the investors more risk taking, will it change the risk landscape? Isn’t there today an ill-balance between the geographical origin of the investment capacities and the areas where projects needing equity investment are teeming?

TRACK 1: Best practices in academia-industry R&D collaborations

  • Artificial Intelligence to speed-up drug discovery: The revolutionary road to advance innovation.
  • A prospective overview of the forthcoming cross-sectorial collaborations and licensing deals between human and animal health
  • Beyond shared means, common strategies to collectively succeed
  • Patient organisations to join the pharma-biotech-academia trio: Is a fourth musketeer calling for a new way to manage alliances?

TRACK 2: Nurturing and licensing early-stage assets

  • What is the right balance between equity, royalties, collaborative research income for the academic institutions in the process of spinning out companies?
  • An overview of the recent joint initiatives to derisk academic-origin assets
  • Questioning TTOs financing models: Could their expected financial outcome bias the tech transfer process?
  • Under pressure: How does the urge to bring rare disease therapies create a new range of business models or collaborative models?

TRACK 3: Early-stage innovation: Identify the right funding sources

  • Are philanthropic and alternative sources of soft funding always a free lunch?
  • Shaping your start-up for an industrial exit or an IPO: Are there choices to be made at the very initial stage?
  • Are immunotherapies a new investment Eldorado?
  • Agnostic or pure players in the biotech sector: Who is getting prominent in the early-stage financing rounds?

They will speak at BioFIT 2018:

  • Jan Adams, Managing Director, EMBL Ventures (DE)
  • Anjan Aralihalli, Venture Partner, CTI Life Sciences Fund II (CA)
  • Caroline Barelle, CEO, Elasmogen (UK)
  • Yann Barrault, Head of Business Development & Licensing, SATT Grand Centre (FR)
  • Jean-Charles Brosse, Partner Healthcare & Life Sciences, Positive Capital (FR)
  • Alain Chevallier, Life Sciences Partner, Truffle Capital (FR)
  • Lucie Ellis, Senior Editor, Pharma Intelligence | Informa (UK)
  • Juan Garcia, CEO, BioSeed Capital (ES)
  • George Hoffman, Co-founder and CEO, Network Immunology (US)
  • Adrian Ibrahim, Head of Technology Transfer, Wellcome Sanger Institute (UK)
  • Steven J. Klein, Vice President, Business Development, IRICoR – Institute for Research in Immunology and Cancer-Commercialization of Research (CA)
  • Peter Leonardi, CEO, OmniCyte (US)
  • Michael Motz, CBO, NETRIS Pharma (FR)
  • Michael L. Salgaller, Supervisor, Invention Development and Marketing Unit, National Institutes of Health (NIH) | National Cancer Institute (NCI) | Technology Transfer Center (US)
  • Bernd Stowasser, Head of Alliance Management Germany & Global Public Private Partnerships, Sanofi (DE)
  • Jonathan Tobin, Investment Director, Arix Bioscience (UK)
  • Ewa Truchanowicz, Life Sciences Lead, University of Birmingham Enterprise (UK)
  • Bram Vanparys, Investment Director, MS Ventures (NL)

Many thanks to Boehringer Ingelheim for joining BioFIT 2018 as a Bronze Sponsor!

Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim  is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.

Join this key BioFIT 2018 sponsor to have the opportunity to:

  • Identify your organisation with the main partnering event in Europe dedicated to tech transfer, academia-industry collaborations, early-stage innovations and seed investment in Life Sciences
  • Highlight your interest in early-stage innovation
  • Present your ideas and technologies to key innovation players in Life Sciences
  • Enhance your visibility on an international scale and be recognised as a key innovative actor
  • Show your expertise thanks to specific communication tools

For more information about the sponsorship opportunities, visit the dedicated site page.

Out of 1,000 BioFIT attendees, 1,000 deals have been generated. The breakdown in terms of nature of deals is the following:

  • 35% of collaborative research projects
  • 30% of licensing deals
  • 15% of equity investment deals
  • 20% of services deals

Estimate based on the measurement of 2015 and 2016 delegates’ outcomes

After an exciting and successful first day at BioFIT 2017, the Future Worlds team arrived early on Wednesday morning at the Palais de la Musique et des Congrès convention centre, ready for another energetic day at Europe’s leading life sciences partnering event in Strasbourg. After filming some footage for the blog of the buzzing convention centre, Brigitte and I interviewed our resident stand spinout Dr Agnieszka Janeczek of Renovos in our second …

Watch the video made by Future Worlds:

> Future Worlds is a startup platform and business incubator championing the innovative commercial opportunities being developed by researchers and students at the University of Southampton.

During BioFIT 2017, attendees could win a full for the next edition (4-5 Dec. in Lille, France)

They just had to take their picture in front of the sponsor wall and post it on Twitter.

 

 
And the winner is … Andersen SA!

 

Discover below and during the Start-ups Slams the most innovative start-ups in specific fields

28th Nov. 2.30-4.00 pm | Innov’ Area

Vascular & Metabolic

  • OP2LYSIS
  • CARDIOR PHARMACEUTICALS
  • EMOSIS
  • APTAMIR THERAPEUTICS

Vaccinology & Virology

  • VAXIANO
  • VIRELIEVE
  • PAR’IMMUNE

29th Nov. 9.00-10.30 am | Innov’ Area

Oncology & Immuno-onco

  • STIPE THERAPEUTICS
  • ELTHERA
  • THERANOVIR
  • CHROMALYS

29th Nov. 2.00-3.30 pm | Innov’ Area

Research tools & Therapeutic Delivery

  • MECACHIPS
  • DYNABIND
  • SIMPLICITYBIO
  • RENOVOS

Ageing & Pain

  • INNOPAIN
  • PRAGMA THERAPEUTICS
  • REMINISCIENCES

Discover who will be attending:

BAYER
BAYER ANIMAL HEALTH
BOEHRINGER INGELHEIM
BOEHRINGER INGELHEIM ANIMAL HEALTH
CEVA
DAIICHI SANKYO
FERRING PHARMACEUTICALS
GSK – GLAXOSMITHKLINE
IPSEN INNOVATION
JOHNSON AND JOHNSON INNOVATION
KISSEI AMERICA
KYORIN EUROPE
LABORATORIOS RUBIO
LFB
LILLY
MERCK
MSD
NOVO NORDISK
PFIZER
ROCHE
SANOFI
SERVIER
TAKEDA
VETOQUINOL
VIRBAC
ZOETIS